BioCentury | May 12, 2014
Company News

IBA Group, Wilex deal

...conjugate (ADC) technology at its Heidelberg Pharma subsidiary in Ladenburg, Germany (see BioCentury, Feb. 3). IBA Group...
BioCentury | Nov 25, 2013
Company News

Ion Beam Applications deal

...The management of Cisbio Bioassays S.A.S., a business unit of Ion Beam Applications, completed a buyout of the...
...screening platform in the U.S. and Europe for drug discovery (see BioCentury, Oct. 1, 2012). Ion Beam Applications S.A....
BioCentury | Jun 3, 2013
Financial News

Ion Beam Applications financial update

...affairs, decommissioning, waste management and accounting treatments. The remaining amount is still being disputed by Ion Beam Applications...
...other claims have been settled or have become immaterial or waived by SK Capital Partners. Ion Beam Applications S.A....
BioCentury | May 20, 2013
Company News

Ion Beam Applications deal

...screening platform in the U.S. and Europe for drug discovery (see BioCentury, Oct. 1, 2012). Ion Beam Applications S.A....
BioCentury | Oct 1, 2012
Company News

IBA Group sales and marketing update

...Cisbio Bioassays, a member of the IBA group, launched its epigenetics toolbox based on the company's homogenous...
...directly in whole cells, and can be used for the screening of potential anti-cancer compounds. IBA Group...
BioCentury | Dec 19, 2011
Clinical News

Redectane 124-Iodine-girentuximab regulatory update

...evidence of the cancer diagnostic's safety and efficacy. At the time, Wilex and commercialization partner IBA Group...
BioCentury | Dec 15, 2011
Company News

Wilex: FDA offers adcomm for Redectane

...evidence of the cancer diagnostic's safety and efficacy. At the time, Wilex and commercialization partner IBA Group...
BioCentury | Jul 4, 2011
Finance

2Q Stock Wrap-Up: Stand and deliver

...Federal Institute for Drugs and Medical Devices recommends against the use of Actos Wilex AG (Xetra:WL6)/IBA Group...
BioCentury | Jun 27, 2011
Regulation

Redectane redirect

...FDA," Wilhelm said. He declined to give examples of potential endpoints or provide a timeline. IBA Group...
...to diagnose clear RCC and is responsible for radio-labeling the antibody. Companies and Institutions Mentioned IBA Group...
BioCentury | Jun 20, 2011
Clinical News

Redectane 124-Iodine-girentuximab regulatory update

...trial provided reasonable evidence of the cancer diagnostic's safety and efficacy. Wilex and commercialization partner IBA Group...
Items per page:
1 - 10 of 26
BioCentury | May 12, 2014
Company News

IBA Group, Wilex deal

...conjugate (ADC) technology at its Heidelberg Pharma subsidiary in Ladenburg, Germany (see BioCentury, Feb. 3). IBA Group...
BioCentury | Nov 25, 2013
Company News

Ion Beam Applications deal

...The management of Cisbio Bioassays S.A.S., a business unit of Ion Beam Applications, completed a buyout of the...
...screening platform in the U.S. and Europe for drug discovery (see BioCentury, Oct. 1, 2012). Ion Beam Applications S.A....
BioCentury | Jun 3, 2013
Financial News

Ion Beam Applications financial update

...affairs, decommissioning, waste management and accounting treatments. The remaining amount is still being disputed by Ion Beam Applications...
...other claims have been settled or have become immaterial or waived by SK Capital Partners. Ion Beam Applications S.A....
BioCentury | May 20, 2013
Company News

Ion Beam Applications deal

...screening platform in the U.S. and Europe for drug discovery (see BioCentury, Oct. 1, 2012). Ion Beam Applications S.A....
BioCentury | Oct 1, 2012
Company News

IBA Group sales and marketing update

...Cisbio Bioassays, a member of the IBA group, launched its epigenetics toolbox based on the company's homogenous...
...directly in whole cells, and can be used for the screening of potential anti-cancer compounds. IBA Group...
BioCentury | Dec 19, 2011
Clinical News

Redectane 124-Iodine-girentuximab regulatory update

...evidence of the cancer diagnostic's safety and efficacy. At the time, Wilex and commercialization partner IBA Group...
BioCentury | Dec 15, 2011
Company News

Wilex: FDA offers adcomm for Redectane

...evidence of the cancer diagnostic's safety and efficacy. At the time, Wilex and commercialization partner IBA Group...
BioCentury | Jul 4, 2011
Finance

2Q Stock Wrap-Up: Stand and deliver

...Federal Institute for Drugs and Medical Devices recommends against the use of Actos Wilex AG (Xetra:WL6)/IBA Group...
BioCentury | Jun 27, 2011
Regulation

Redectane redirect

...FDA," Wilhelm said. He declined to give examples of potential endpoints or provide a timeline. IBA Group...
...to diagnose clear RCC and is responsible for radio-labeling the antibody. Companies and Institutions Mentioned IBA Group...
BioCentury | Jun 20, 2011
Clinical News

Redectane 124-Iodine-girentuximab regulatory update

...trial provided reasonable evidence of the cancer diagnostic's safety and efficacy. Wilex and commercialization partner IBA Group...
Items per page:
1 - 10 of 26